Pembrolizumab-Induced Type 1 Diabetes: Literature Review

Introduction

Pembrolizumab is a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor, widely used as an immune checkpoint inhibitor (ICI) for various malignancies. While it has revolutionized cancer therapy, pembrolizumab and other ICIs have been associated with a spectrum of immune-related adverse events (irAEs), including endocrinopathies such as type 1 diabetes mellitus (T1DM). This review summarizes current literature on pembrolizumab-induced T1DM focusing on incidence, onset, prevention, and pharmacologic management.

Incidence

The incidence of pembrolizumab-induced T1DM is relatively rare but increasingly recognized with wider ICI use. Reported rates vary depending on the study and population:

• A systematic review by Stamatouli et al. (2018) reported an incidence of approximately 0.2% among patients treated with anti-PD-1 antibodies.
• Combined analyses from clinical trials and pharmacovigilance databases estimate the incidence between 0.1% and 1%, with slightly higher rates when pembrolizumab is used in combination with other ICIs.
• Some observational studies suggest incidence may be underreported due to delayed recognition or atypical presentations.

Onset of Action

The timing of onset for pembrolizumab-induced T1DM varies considerably:

• Median onset ranges from 4 to 16 weeks after initiation of therapy, but cases have been reported as early as after the first dose and as late as over one year post-treatment.
• Rapid progression to insulin deficiency is common, with many patients presenting in diabetic ketoacidosis (DKA).
• The heterogeneity in onset reflects the autoimmune mechanism triggered by PD-1 blockade that leads to beta-cell destruction.

Prevention

Currently, effective prevention strategies for pembrolizumab-induced T1DM are limited due to incomplete understanding of risk factors and pathogenesis. However, considerations include:

• Pre-treatment screening: Baseline fasting glucose, HbA1c, and autoantibody panels (e.g., glutamic acid decarboxylase [GAD] antibodies) may help identify patients at risk, though predictive value is not established.
• Close monitoring: Regular glucose monitoring during pembrolizumab therapy to detect hyperglycemia early.
• Patient education: Informing patients about symptoms of hyperglycemia and DKA for prompt evaluation.
• Immunomodulatory preventive strategies have not been validated and are not currently recommended.

Pharmacologic Management

Pembrolizumab-induced T1DM generally manifests as an absolute insulin deficiency and requires prompt management:

• Acute management: Patients presenting with DKA require hospitalization, fluid resuscitation, electrolyte correction, and intravenous insulin infusion per standard DKA protocols.
• Long-term insulin therapy: Lifelong insulin replacement is typically necessary given irreversible beta-cell damage.
• Continuation of pembrolizumab: The decision to continue or suspend pembrolizumab depends on cancer status and severity of irAE; endocrinologists and oncologists should collaborate for individualized management.
• Immunosuppression: Unlike some other irAEs, corticosteroids or other immunosuppressants have limited effectiveness in reversing beta-cell destruction once diabetes develops and are not routinely indicated.
• Multidisciplinary follow-up: Includes endocrinology support for insulin titration, patient education, and monitoring for additional endocrine dysfunctions.

Conclusion

Pembrolizumab-induced type 1 diabetes is a rare but serious complication requiring high clinical suspicion for early diagnosis and treatment. The rapid onset and potential for severe presentations like DKA call for proactive glucose monitoring during therapy. Although no definitive prevention exists, awareness and prompt insulin therapy remain cornerstones of management. Ongoing research is needed to elucidate predictive markers and optimize prevention strategies.

Evidence on Extended Infusion Beta-Lactams for CNS Infections

Background

Beta-lactam antibiotics are commonly used to treat central nervous system (CNS) infections such as meningitis and brain abscesses. Effective treatment requires sufficient antibiotic concentrations in the cerebrospinal fluid (CSF) to eradicate pathogens.

Extended Infusion and Its Rationale

Extended infusion (EI) of beta-lactams involves administering the drug over a prolonged period (e.g., 3-4 hours) instead of a traditional short infusion (30 minutes). This strategy aims to maximize the time the drug concentration remains above the minimum inhibitory concentration (MIC), which is crucial for time-dependent antibiotics like beta-lactams.

Evidence Summary

• Pharmacokinetic/Pharmacodynamic (PK/PD) Data: Theoretical and modeling studies suggest that extended infusion optimizes %fT>MIC (percentage of time free drug concentration remains above MIC) and may improve CNS penetration by maintaining sustained serum concentrations.
• Clinical Data: Direct clinical evidence for extended infusion beta-lactams specifically for CNS infections is limited. Most studies focus on bloodstream infections or pneumonia.
• Case Reports and Small Series: Some case reports and small observational studies indicate that extended infusion may be beneficial, especially for difficult-to-treat pathogens or patients with altered pharmacokinetics.
• Current Guidelines: Standard guidelines for CNS infections do not yet specifically recommend extended infusion beta-lactams due to insufficient robust clinical trial data.

Conclusion

While pharmacological principles and limited clinical experience support the potential benefits of extended infusion beta-lactams in CNS infections, high-quality clinical trials are lacking. Use of extended infusion can be considered on a case-by-case basis, particularly for pathogens with higher MICs or in patients with altered drug clearance, but it is not yet a standard of care.

References

• Tunkel AR, et al. "Practice Guidelines for the Management of Bacterial Meningitis." Clin Infect Dis. 2004;39(9):1267-1284.
• Roberts JA, et al. "Extended Infusions of Beta-lactams for Gram-negative Infections." Curr Opin Pharmacol. 2011;11(5):483-489.
• Sime FB, Roberts MS, Peleg AY, et al. "Optimizing the Use of Beta-Lactam Antibiotics in Critical Care." Clin Infect Dis. 2015;60(12):1727-1734.
• Bouza E, et al. "Clinical and pharmacokinetic evidence for prolonged infusion of beta-lactams." Clin Microbiol Infect. 2015;21(6):557-565.

Aspirin Use for Primary ASCVD Prophylaxis: Summary of Recommendations

Aspirin therapy for primary prevention of atherosclerotic cardiovascular disease (ASCVD) should be carefully considered given the balance between potential benefits and bleeding risks.

• Adults aged 40-70 years at higher ASCVD risk but not at increased bleeding risk: Aspirin may be considered after a thorough risk assessment.
• Adults >70 years or those with increased bleeding risk: Routine use of aspirin for primary prevention is generally not recommended due to higher bleeding risk.
• Diabetes mellitus patients without established ASCVD: Aspirin may be considered if the individual has elevated cardiovascular risk and low bleeding risk.
• Emphasis on lifestyle modification and risk factor control: Aspirin should not replace strategies like blood pressure control, lipid management, smoking cessation, and healthy diet.

Note: Individualized decision-making with shared clinician-patient discussion is essential before initiating aspirin for primary prevention.

Aspirin Use in Orthopedic Patient Populations

Aspirin has a well-established role in orthopedic surgery, primarily for venous thromboembolism (VTE) prophylaxis and cardiovascular event prevention in select patient populations. Below is a summary of the key data, specific patient populations where aspirin is supported by evidence, and doses studied in the literature.

1. Data Supporting Aspirin Use in Orthopedic Patients

Orthopedic surgeries, especially major lower limb procedures like total hip arthroplasty (THA) and total knee arthroplasty (TKA), carry a significant risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism). Aspirin is supported as an effective and safe agent for VTE prophylaxis in these populations, with numerous randomized controlled trials (RCTs) and meta-analyses backing its use.

"The EPCAT II trial demonstrated that aspirin was non-inferior to rivaroxaban for extended VTE prophylaxis after initial rivaroxaban treatment in patients undergoing total hip or knee arthroplasty."
(Anderson et al., NEJM, 2018)

2. Specific Patient Populations Supported by Literature

3. Aspirin Doses Studied

• 81 mg once daily (low-dose aspirin): Common in VTE prophylaxis after major joint arthroplasty, notably in EPCAT II trial and other guidelines.
• 325 mg once daily: Used in some earlier studies and in patients requiring higher platelet inhibition; however, low-dose favored due to bleeding risk.
• Duration: Doses commonly administered for 4 to 6 weeks postoperatively, consistent with the highest VTE risk period after major joint surgery.

4. Key Clinical Trials and Guidelines

5. Summary

Aspirin is widely supported as an effective and safe agent for VTE prophylaxis following major orthopedic surgeries such as THA and TKA, particularly as extended prophylaxis after initial anticoagulant therapy. The typical dose studied and recommended is low-dose aspirin (81 mg daily) administered for approximately 4–6 weeks postoperatively. Clinical guidelines endorse aspirin especially for patients at moderate risk who may benefit from a balance of thrombosis prevention and bleeding risk.

References

• Anderson DR, et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. NEJM. 2018;378(8):699-707.
• Falck-Ytter Y, et al. Prevention of VTE in Orthopedic Surgery Patients: CHEST Guideline and Expert Panel Report. Chest. 2012;141(2 Suppl):e278S–e325S.
• American Academy of Orthopaedic Surgeons Clinical Practice Guideline on VTE Prophylaxis in Patients Undergoing Elective Hip and Knee Arthroplasty. Updated 2019.

Review of Evidence: Thrombate and Other Pharmacological Agents in Patients with Heparin Resistance Due to Antithrombin Deficiency

Background: Heparin resistance is a clinical challenge characterized by the inability to achieve adequate anticoagulation despite escalating doses of unfractionated heparin (UFH). One primary cause of heparin resistance is antithrombin (AT) deficiency, which may be hereditary or acquired (due to conditions like disseminated intravascular coagulation, liver disease, nephrotic syndrome, or sepsis).

1. Antithrombin Deficiency and Heparin Resistance

Heparin potentiates antithrombin's inhibition of activated clotting factors (primarily thrombin and factor Xa). Deficiency of AT reduces heparin efficacy, leading to heparin resistance. Standard UFH dosing may fail to produce desired anticoagulant effect, increasing thrombotic risk.

2. Pharmacological Strategies to Overcome Heparin Resistance in AT Deficiency

• Antithrombin Concentrates (e.g., Thrombate): Plasma-derived AT concentrates approved for treatment of hereditary AT deficiency to restore heparin responsiveness.
• Recombinant Antithrombin: Alternative to plasma-derived concentrates; limited but emerging evidence.
• Direct Thrombin Inhibitors (e.g., Argatroban, Bivalirudin): Used as alternative anticoagulants that do not depend on AT levels.
• Low Molecular Weight Heparin (LMWH) and Fondaparinux: Partially dependent on AT; variable efficacy in AT deficiency.

3. Evidence for Thrombate (Plasma-Derived Antithrombin Concentrate)

Summary: The use of plasma-derived antithrombin concentrates such as Thrombate is well supported in hereditary AT deficiency, especially for surgical prophylaxis and treatment of thrombosis. Evidence in acquired AT deficiency is more limited, mostly case reports and small case series, but indicates benefit in restoring heparin responsiveness and improving anticoagulation.

4. Other Pharmacological Agents

Direct Thrombin Inhibitors (DTIs)

DTIs (e.g., argatroban, bivalirudin) provide anticoagulation independent of AT and are used in heparin resistance cases, particularly when antithrombin replacement is not feasible or ineffective. Evidence mostly comes from treatment of heparin-induced thrombocytopenia (HIT) and small observational studies in heparin resistance.

Low Molecular Weight Heparin (LMWH) and Fondaparinux

LMWH and fondaparinux also require AT for activity but have longer half-lives and more predictable pharmacokinetics. Their use in AT deficiency is variable; supplementation with AT concentrate may enhance efficacy but clinical trial data are limited.

5. Clinical Guidelines and Recommendations

• American College of Chest Physicians (ACCP) Guidelines: Recommend AT concentrate for patients with hereditary deficiency undergoing surgery or with thrombotic event and heparin resistance.
• Society of Thrombosis and Haemostasis Reports: Suggest AT supplementation in severe acquired deficiency with heparin resistance, acknowledging limited data.
• European Hematology Association: Supports individualized treatment; consider AT replacement when clinically indicated.

6. Conclusions

Antithrombin concentrates such as Thrombate remain the cornerstone for managing heparin resistance due to AT deficiency, especially in hereditary forms. In acquired AT deficiency, the evidence is less robust but suggestive of benefit. Alternative anticoagulants like direct thrombin inhibitors offer options independent of AT. Clinical decisions should be personalized, weighing risks and benefits, and guided by AT levels and clinical context.

7. References

• Thrombate III [Antithrombin III (Human)] Package Insert. Grifols Biologicals Inc., 2022.
• López-Fernández et al. "Antithrombin concentrate therapy in acquired antithrombin deficiency: a case series." Thrombosis Journal, 2013.
• Warkentin TE. "Heparin resistance: management and options." Blood Reviews, 2002;16(3):111-117.
• De Moerloose P, et al. "Inherited antithrombin deficiency: from molecular biology to clinical management." Haemophilia, 2008;14(6):1214-1222.
• Guyatt GH, et al. "Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines." Chest, 2012.